Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary ProxyGlobeNewsWire • 02/27/23
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023GlobeNewsWire • 02/24/23
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023GlobeNewsWire • 02/23/23
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and AdvocacyGlobeNewsWire • 01/18/23
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A.GlobeNewsWire • 01/11/23
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease CompanyGlobeNewsWire • 01/09/23
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)GlobeNewsWire • 12/21/22
KemPharm Announces Appointment of Christopher Posner as New Independent DirectorGlobeNewsWire • 11/29/22
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)GlobeNewsWire • 11/18/22
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19thGlobeNewsWire • 10/04/22
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)GlobeNewsWire • 09/28/22
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/01/22
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate CommunicationsGlobeNewsWire • 08/09/22